(Q40656868)

22 September 2017

1 reference

title

Medical management of chronic inflammatory bowel disease (English)

1 reference

inflammatory bowel diseases

22 September 2017

main subject

1 reference

Murch SH

1

1 reference

22 September 2017

Walker-Smith JA

series ordinal

2

1 reference

22 September 2017

publication date

1 March 1994

1 reference

Bailliere's clinical gastroenterology

22 September 2017

published in

1 reference

22 September 2017

volume

8

1 reference

22 September 2017

issue

1

1 reference

22 September 2017

page(s)

133-148

1 reference

Oral fluticasone propionate in active distal ulcerative colitis

22 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2806%2980023-0

7 January 2021

Inflammatory bowel disease in childhood

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2806%2980023-0

7 January 2021

Healing of severe perineal and cutaneous Crohn's disease with hyperbaric oxygen

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2806%2980023-0

7 January 2021

A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2806%2980023-0

7 January 2021

A meta-analysis of the role of smoking in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2806%2980023-0

7 January 2021

Inhibition of binding of interferon-gamma to its receptor by salicylates used in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2806%2980023-0

7 January 2021

Surgery for Crohn's disease in childhood: influence of site of disease and operative procedure on outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2806%2980023-0

7 January 2021

Tumour-necrosis-factor antibody treatment in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2806%2980023-0

7 January 2021

Treatment of inflammatory bowel disease with anti-CD4 monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2806%2980023-0

7 January 2021

Response to heparin in patients with ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2806%2980023-0

7 January 2021

Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID)

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2806%2980023-0

7 January 2021

Inhibition of leucocyte adhesion molecule upregulation by tumor necrosis factor alpha: a novel mechanism of action of sulphasalazine

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2806%2980023-0

7 January 2021

Prooxidant properties of 5-aminosalicylic acid. Possible mechanism for its adverse side effects

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2806%2980023-0

7 January 2021

Treatment of ulcerative colitis with fish oil supplementation: a prospective 12 month randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2806%2980023-0

7 January 2021

Double blind trial of oral fluticasone propionate v prednisolone in the treatment of active ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2806%2980023-0

7 January 2021

Cyclosporin in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2806%2980023-0

7 January 2021

Remission of Crohn's disease after human immunodeficiency virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2806%2980023-0

7 January 2021

Fluticasone propionate in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2806%2980023-0

7 January 2021

Agents capable of eliminating reactive oxygen species. Catalase, WR-2721, or Cu(II)2(3,5-DIPS)4 decrease experimental colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2806%2980023-0

7 January 2021

New treatment of ulcerative colitis with K-76

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2806%2980023-0

7 January 2021

Sucralfate enema in ulcerative rectosigmoid lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2806%2980023-0

7 January 2021

Endoscopic monitoring of Crohn's disease treatment: a prospective, randomized clinical trial. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2806%2980023-0

7 January 2021

Treatment of Crohn's disease with fusidic acid: an antibiotic with immunosuppressive properties similar to cyclosporin

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2806%2980023-0

7 January 2021

Testing nicotine gum for ulcerative colitis patients. Experience with single-patient trials

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2806%2980023-0

7 January 2021

Azathioprine and 6-mercaptopurine have a role in the treatment of Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2806%2980023-0

7 January 2021

Role of oxygen free radicals in the etiology of pouchitis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2806%2980023-0

7 January 2021

Acceleration of linear growth following intestinal resection for Crohn disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2806%2980023-0

7 January 2021

Inhibition of antibody secretion by 5-aminosalicylic acid.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2806%2980023-0

7 January 2021

5-Aminosalicylic acid is a potent inhibitor of interleukin 1 beta production in organ culture of colonic biopsy specimens from patients with inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2806%2980023-0

7 January 2021

Anorexia nervosa complicating inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2806%2980023-0

7 January 2021

Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2806%2980023-0

7 January 2021

Smoking, eicosanoids and ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2806%2980023-0

7 January 2021

Disruption of sulphated glycosaminoglycans in intestinal inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2806%2980023-0

7 January 2021

Effect of the leukotriene LTD4/LTE4 antagonist, SR 2640, in ulcerative colitis: an open clinical study

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2806%2980023-0

7 January 2021

Double blind, controlled trial of 4-aminosalicylic acid and prednisolone enemas in distal ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2806%2980023-0

7 January 2021

A comparison of sucralfate and prednisolone enemas in the treatment of active distal ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2806%2980023-0

7 January 2021

Rifabutin and ethambutol do not help recurrent Crohn's disease in the neoterminal ileum

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2806%2980023-0

7 January 2021

Treatment of ulcerative colitis with fish oil n--3-omega-fatty acid: an open trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2806%2980023-0

7 January 2021

Cyclosporine treatment of inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2806%2980023-0

7 January 2021

Measurement of colonic tissue cyclosporine concentration in children with severe ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2806%2980023-0

7 January 2021

Remission induced by an elemental diet in small bowel Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2806%2980023-0

7 January 2021

Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2806%2980023-0

7 January 2021

Effect of cigarette smoking on recurrence of Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2806%2980023-0

7 January 2021

Scavenging effect of 5-aminosalicylic acid on neutrophil-derived oxidants. Possible contribution to the mechanism of action in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2806%2980023-0

7 January 2021

Cyclosporine treatment of severe ulcerative colitis in children

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2806%2980023-0

7 January 2021

Pathogenesis of Crohn's disease: multifocal gastrointestinal infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2806%2980023-0

7 January 2021

10.1016/S0950-3528(06)80023-0

Identifiers

DOI

1 reference

release_3t3ccvvd7fau3hvleswdzh5nxq

22 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/3t3ccvvd7fau3hvleswdzh5nxq

24 November 2022

mapped directly with Wikidata item

1 reference